MA46721A - Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 - Google Patents

Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137

Info

Publication number
MA46721A
MA46721A MA046721A MA46721A MA46721A MA 46721 A MA46721 A MA 46721A MA 046721 A MA046721 A MA 046721A MA 46721 A MA46721 A MA 46721A MA 46721 A MA46721 A MA 46721A
Authority
MA
Morocco
Prior art keywords
ctla
listeria
antibodies
combination
based vaccine
Prior art date
Application number
MA046721A
Other languages
English (en)
Inventor
Sandra M Hayes
Rachelle Kosoff
Jun Zou
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MA46721A publication Critical patent/MA46721A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA046721A 2016-11-07 2017-11-07 Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 MA46721A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662418690P 2016-11-07 2016-11-07

Publications (1)

Publication Number Publication Date
MA46721A true MA46721A (fr) 2019-09-11

Family

ID=62076388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046721A MA46721A (fr) 2016-11-07 2017-11-07 Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137

Country Status (4)

Country Link
US (1) US20200061167A1 (fr)
EP (1) EP3534944A4 (fr)
MA (1) MA46721A (fr)
WO (1) WO2018085854A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
RU2016145464A (ru) 2014-04-24 2018-05-24 Адваксис, Инк. Рекомбинантные вакцинные штаммы listeria и способы их получения
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
WO2019060115A1 (fr) 2017-09-19 2019-03-28 Advaxis, Inc. Compositions et procédés de lyophilisation de bactéries ou de souches de listeria
EP3730153A1 (fr) 2019-04-26 2020-10-28 Medizinische Hochschule Hannover Immunothérapie personnalisée pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404164A1 (fr) * 2000-03-29 2001-10-04 The Trustees Of The University Of Pennsylvania Compositions et procedes renforcant l'immunogenicite d'antigenes
EP1434596B1 (fr) * 2001-10-09 2009-07-08 Mayo Foundation For Medical Education And Research Amelioration des reponses immunitaires par des anticorps agonistes liant 4-1bb
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
WO2010042433A1 (fr) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
MA41218A (fr) * 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr

Also Published As

Publication number Publication date
EP3534944A4 (fr) 2020-07-01
US20200061167A1 (en) 2020-02-27
WO2018085854A1 (fr) 2018-05-11
EP3534944A1 (fr) 2019-09-11

Similar Documents

Publication Publication Date Title
MA46721A (fr) Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137
MA41218A (fr) Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
MA49043A (fr) Formulation stable d'anticorps
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
MA49033A (fr) Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA44780A (fr) Préparation contenant un anticorps
MA44077A (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA55043A (fr) Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MX2022002106A (es) Formulaciones de vacuna de vial unico.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MA54052A (fr) Formulation d'anticorps
MA44236A (fr) Anticorps anti-tgfbêta 2
DK3515918T3 (da) Fremgangsmåde til fremstilling af 2-exo-(2-methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptan
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA51212A (fr) Anticorps neutralisant les polyomavirus